# Bevacizumab In Hereditary Hemorrhagic Telangiectasia

> **NCT04404881** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Hanny Al-Samkari, MD** · enrollment: 33 (actual)

## Conditions studied

- Hereditary Hemorrhagic Telangiectasia

## Interventions

- **DRUG:** Bevacizumab (Avastin®)

## Key facts

- **NCT ID:** NCT04404881
- **Lead sponsor:** Hanny Al-Samkari, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-11-23
- **Primary completion:** 2026-03-02
- **Final completion:** 2027-02-01
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04404881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04404881, "Bevacizumab In Hereditary Hemorrhagic Telangiectasia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04404881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*